Eyelash Growth Treatment Online in California

Yes. California Business and Professions Code Section 2290.5 permits licensed physicians to prescribe appropriate medications via synchronous video telehealth without a prior in-person visit. TeleDirectMD's California-licensed board-certified Family Medicine physician evaluates your eyelash growth concerns, screens for contraindications including glaucoma and intraocular pressure medications, and prescribes Latisse (bimatoprost 0.03%) for eligible patients. Self pay is $79; Aetna is in-network effective April 30, 2026.

Latisse (bimatoprost ophthalmic solution 0.03%) is the only FDA-approved prescription medication for hypotrichosis of the eyelashes — insufficient eyelash growth. It is a prostaglandin analog that extends the anagen (growth) phase of the eyelash hair cycle and increases the number of hairs in the growth phase. Applied nightly to the upper eyelid margin, Latisse produces measurable increases in eyelash length, fullness, and darkness by 16 weeks in the FDA approval trial. Results are reversible — eyelashes return to baseline within weeks to months of discontinuation.

Latisse has been FDA-approved since 2008 and has a well-characterized safety profile when used as directed. Known risks include: eyelid skin darkening at the application site (typically reversible with discontinuation); very rare iris color change (more relevant for ophthalmic drops used for glaucoma than for the cosmetic eyelid application); periorbital fat atrophy with long-term use (infrequent at cosmetic doses); and transient eye irritation or itching. The physician screens for contraindications — active eye infection, glaucoma without ophthalmologist coordination, pregnancy — before prescribing.

Bimatoprost (the active ingredient in Latisse) is also used as prescription eye drops (Lumigan) to lower intraocular pressure in glaucoma. When applied to the upper eyelid skin margin as directed — rather than directly to the eye as drops — systemic absorption and IOP effects are minimal. However, the physician screens all patients for glaucoma, elevated IOP, and current IOP-lowering medications before prescribing Latisse, and recommends that patients with glaucoma inform their ophthalmologist before starting Latisse.

Apply Latisse once nightly following this technique: remove makeup and contact lenses first; place one drop of Latisse onto the provided sterile applicator brush (do not re-use applicators); draw the brush along the upper eyelid margin at the skin at the base of the upper eyelashes, moving from the inner to outer corner; blot any excess solution from the eyelid with a clean tissue (to minimize off-target effects); wait 15 minutes before reinserting contact lenses. Do NOT apply to the lower eyelid margin — this causes unwanted hair growth on the lower eyelid skin.

Latisse (bimatoprost 0.03%) is not available as an FDA-approved generic in the U.S. for the cosmetic eyelash indication. Brand Latisse costs approximately $120–$200 per 3 mL or 5 mL bottle at California pharmacies with a GoodRx coupon as of May 2026. Allergan (manufacturer) offers savings programs through their website that can significantly reduce out-of-pocket cost. The $79 TeleDirectMD visit covers the physician evaluation and prescription — the Latisse medication cost is a separate out-of-pocket expense.

Latisse is generally considered a cosmetic prescription and is not covered by most commercial health insurance plans including Aetna and UnitedHealthcare for the cosmetic eyelash growth indication. The TeleDirectMD self-pay visit rate of $79 covers the physician evaluation and prescription — the Latisse medication cost ($120–$200) is a separate out-of-pocket expense. Allergan manufacturer savings programs can help reduce drug cost. Medi-Cal does not cover Latisse for cosmetic purposes.

Before prescribing Latisse, the physician screens for secondary causes of eyelash loss: hypothyroidism (TSH check if eyelash AND eyebrow thinning present — classic hypothyroidism sign), alopecia areata (autoimmune), chemotherapy-induced alopecia (grows back after chemo ends), trichotillomania, eyelid inflammatory conditions (blepharitis, seborrheic dermatitis), and nutritional deficiencies (iron deficiency, biotin — though biotin supplementation is commonly oversold with little evidence). Treating an underlying cause is appropriate before starting Latisse for secondary eyelash loss.

Latisse results are not permanent — they depend on continued use. Eyelash growth improvements typically begin at 4 weeks and reach maximum effect at 16 weeks. Upon discontinuation, eyelashes gradually return to their baseline appearance within weeks to months. Most patients use Latisse as ongoing maintenance therapy — once nightly on weekdays with occasional weekends off is a common approach some patients use to reduce cost while maintaining most of the benefit. The physician discusses the duration strategy at the initial visit.

Yes. California Business and Professions Code Section 2290.5 does not require a prior in-person visit for telehealth prescribing of non-controlled medications. Latisse (bimatoprost) is not a controlled substance and can be prescribed via a California video visit after the physician screens for contraindications. The Medical Board of California holds telehealth physicians to the same standard of care as in-person physicians — which TeleDirectMD satisfies through comprehensive contraindication screening and prescribing education at every visit.

Latisse is FDA-approved for eyelash hypotrichosis only. Eyebrow application is off-label — some physicians use bimatoprost off-label for eyebrow growth with patient informed consent. The physician discusses whether eyebrow application is appropriate for your individual situation. When applied to eyebrow skin, the same safety considerations apply — application site skin darkening and proximity to the eye are relevant. Eyebrow thinning may also indicate hypothyroidism (lateral third eyebrow thinning is a classic sign) — the physician screens for thyroid disease if eyebrow loss is the primary concern.

At the consultation, the physician reviews: current eyelash status (photos or live video), prior Latisse or prostaglandin analog use, glaucoma history and current eye medications, contact lens use, any active eye infections or eyelid conditions, pregnancy or breastfeeding status, and any medications that could interact with bimatoprost. After screening, the physician prescribes a 3 mL bottle (approximately 90-day supply) with detailed application instructions. Follow-up is available if side effects occur. Self pay is $79 per visit.